Lessons from withdrawn accelerated approvals in oncology
Nat Cancer
.
2024 Feb;5(2):211-215.
doi: 10.1038/s43018-023-00696-8.
Authors
George S Mellgard
1
,
Tito Fojo
2
3
4
,
Susan E Bates
5
6
7
Affiliations
1
Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
2
Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA. atf2116@cumc.columbia.edu.
3
James J. Peters Department of Veterans Affairs Medical Center, Bronx, NY, USA. atf2116@cumc.columbia.edu.
4
Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY, USA. atf2116@cumc.columbia.edu.
5
Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA. seb2227@cumc.columbia.edu.
6
James J. Peters Department of Veterans Affairs Medical Center, Bronx, NY, USA. seb2227@cumc.columbia.edu.
7
Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY, USA. seb2227@cumc.columbia.edu.
PMID:
38291305
DOI:
10.1038/s43018-023-00696-8
No abstract available
MeSH terms
Antineoplastic Agents* / therapeutic use
Medical Oncology*
Substances
Antineoplastic Agents